Literature DB >> 7011110

The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.

J De Cree, J Leempoels, W De Cock, H Geukens, H Verhaegen.   

Abstract

In a first experiment, an acute intravenous administration of 10 mg R 41 468, a pure serotonin-receptor blocking agent with high selectivity for blood vessels and thrombocytes and devoid of central effects, dramatically reduced systolic and diastolic blood pressure in 23 elderly hypertensive patients. Heart rate and cardiac output remained virtually unchanged. In a second double-blind placebo-controlled cross-over study a highly significant decrease of systolic and diastolic blood pressure was obtained in 14 elderly hypertensive patients during an 8-day oral treatment with 40 mg t.i.d. of R 41 468. No serious side-effects were observed. An oral maintenance therapy with R 41 468 for 3 weeks showed a further reduction of blood pressure, resulting in a normalization of blood pressure, taking into account the advanced age of the patients. R 41 468 most probably acts by decreasing the venous capacitance bed constriction. Essential hypertension might be causally related to an impairment of venous function, in which serotonin might be an important pressor factor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011110     DOI: 10.1177/000331978103200206

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  12 in total

1.  Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.

Authors:  C Bartoloni; P Dupont; H Feltkamp; C I Johnston; K Steinbach; H Zilcher; F Kaindl
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Bioavailability and pharmacokinetics of ketanserin in elderly subjects.

Authors:  M Kurowski
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Pharmacokinetics of ketanserin in man.

Authors:  I W Reimann; P O Okonkwo; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Ketanserin without effects on basal anterior pituitary hormone secretion in healthy subjects.

Authors:  A Gordin; P Mustajoki; R Pelkonen
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

5.  The relevance of serotonin antagonism in the treatment of hypertension.

Authors:  A E Doyle
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.

Authors:  T Hedner; B Persson; G Berglund
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

Review 7.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

8.  In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.

Authors:  S Conolan; M J Quinn; D A Taylor
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

9.  The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.

Authors:  J De Cree; J Leempoels; B Demoen; V Roels; H Verhaegen
Journal:  Agents Actions       Date:  1985-07

10.  Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.

Authors:  T Hedner; B Persson
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.